Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Candel Therapeutics, Inc. (CADL)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 28,690,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Candel Therapeutics is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Co. has oncolytic viral immunotherapy platforms based on genetically modified adenovirus and herpes simplex virus constructs. Co.'s product candidate, CAN-2409, is an off-the-shelf adenovirus product candidate combined with the prodrug valacyclovir. Co. is conducting, as part of its CAN-2409 program, a clinical trial in the U.S. for CAN-2409 in patients with newly diagnosed localized prostate cancer who have an intermediate- or high-risk for progression. Co. is also developing its HSV platform product candidates for solid tumor indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 1,250,000 1,250,000 1,250,000
Total Buy Value $0 $7,500,000 $7,500,000 $7,500,000
Total People Bought 0 1 1 1
Total Buy Transactions 0 1 1 1
Total Shares Sold 139,912 279,571 597,363 597,363
Total Sell Value $1,228,408 $2,307,127 $4,128,230 $4,128,230
Total People Sold 5 5 6 6
Total Sell Transactions 6 16 36 36
End Date 2025-03-16 2024-12-13 2024-06-14 2023-06-15

   
Records found: 123
  Page 1 of 5  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Tak Paul Peter Chief Executive Officer   •       •      –    2025-03-19 4 AS $9.00 $3,601 D/D (400) 225,740     -
   Tak Paul Peter Chief Executive Officer   •       •      –    2025-03-18 4 AS $8.77 $226,023 D/D (25,772) 226,140     -
   Nichols Garrett Chief Medical Officer   •       –      –    2025-03-18 4 AS $8.76 $396,995 D/D (45,316) 52,493     -
   Nichols Garrett Chief Medical Officer   •       –      –    2025-03-18 4 OE $1.29 $35,127 D/D 18,489 97,809     -
   Barone Francesca Chief Scientific Officer   •       –      –    2025-03-18 4 AS $8.76 $281,673 D/D (32,146) 96,527     -
   Barone Francesca Chief Scientific Officer   •       –      –    2025-03-18 4 OE $1.55 $27,900 D/D 18,000 128,673     -
   Tyagarajan Seshu Chief Technology Officer   •       –      –    2025-03-17 4/A OE $1.29 $25,800 D/D 20,000 116,790     -
   Schoch Charles See Remarks   •       –      –    2025-03-17 4 AS $8.83 $44,169 D/D (5,000) 38,038     -
   Tyagarajan Seshu Chief Technology Officer   •       –      –    2025-03-17 4 AS $8.82 $275,947 D/D (31,278) 85,512     -
   Aguilar Laura K. 10% Owner   –       –       •   2025-02-21 4 D $12.02 $127,208 D/D (10,583) 162,929     -
   Aguilar Laura K. 10% Owner   –       –       •   2025-02-21 4 D $12.02 $127,196 I/I (10,582) 120,861     -
   Aguilar Laura K. 10% Owner   –       –       •   2025-02-10 4 D $8.61 $269,794 D/D (31,335) 60,000     -
   Nichols Garrett Chief Medical Officer   •       –      –    2025-01-15 4 S $7.23 $75,342 D/D (10,428) 79,320     -
   Barone Francesca Chief Scientific Officer   •       –      –    2025-01-15 4 S $7.23 $97,783 D/D (13,534) 110,673     -
   Tyagarajan Seshu Chief Technology Officer   •       –      –    2025-01-15 4 S $7.23 $103,476 D/D (14,322) 96,790     -
   Tak Paul Peter Chief Executive Officer   •       •      –    2025-01-15 4 S $7.23 $156,811 D/D (21,704) 251,912     -
   Schoch Charles See Remarks   •       –      –    2025-01-15 4 S $7.23 $68,717 D/D (9,511) 43,038     -
   Schoch Charles See Remarks   •       –      –    2025-01-08 4 S $8.22 $81,944 D/D (9,971) 52,549     -
   Tyagarajan Seshu Chief Technology Officer   •       –      –    2025-01-08 4 S $8.22 $119,534 D/D (14,545) 111,112     -
   Barone Francesca Chief Scientific Officer   •       –      –    2025-01-08 4 S $8.22 $112,367 D/D (13,673) 124,207     -
   Nichols Garrett Chief Medical Officer   •       –      –    2025-01-08 4 S $8.22 $88,749 D/D (10,799) 89,748     -
   Tak Paul Peter Chief Executive Officer   •       •      –    2025-01-08 4 S $8.22 $173,996 D/D (21,172) 273,616     -
   Aguilar Laura K. 10% Owner   –       –       •   2024-12-27 4 D $8.85 $442,500 I/I (50,000) 131,443     -
   Aguilar Laura K. 10% Owner   –       –       •   2024-12-27 4 D $8.85 $442,500 D/D (50,000) 173,512     -
   Aguilar Laura K. 10% Owner   –       –       •   2024-12-26 4 D $9.01 $450,500 I/I (50,000) 181,443     -
  123 Records found
  1  2  3  4  5   
  Page 1 of 5
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us